Article metrics
PDF
Other content recommended for you
- Management of chronic migraine
- Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine
- Three new drugs for the prevention of migraine
- Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial
- Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series
- Oral once a day treatment for migraine
- Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat
- 4CPS-354 Efficacy and safety with erenumab and galcanezumab: our experience
- Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
- Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects